Avenue Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Avenue Therapeutics Stock Summary

Avenue Therapeutics competes with Capricor Therapeutics, Soleno Therapeutics, Bio Path, Moleculin Biotech, and Crinetics Pharmaceuticals. Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acuteintensive care hospital setting. The company was incorporated in 2015 and is based in New York, New York. Avenue Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.

Avenue Therapeutics Key Financial Ratios

Avenue Therapeutics Key Balance Sheet Accounts

Avenue Therapeutics Key Income Statement Accounts

Avenue Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Avenue Therapeutics's current stock value. Our valuation model uses many indicators to compare Avenue Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Avenue Therapeutics competition to find correlations between indicators driving Avenue Therapeutics's intrinsic value. More Info.Avenue Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Avenue Therapeutics' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Avenue Therapeutics' earnings, one of the primary drivers of an investment's value.

Avenue Therapeutics Systematic Risk

Today, most investors in Avenue Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Avenue Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Avenue Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Avenue Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Avenue Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Avenue Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Avenue Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Avenue Therapeutics's daily price indicators and compare them against related drivers.

When running Avenue Therapeutics' price analysis, check to measure Avenue Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avenue Therapeutics is operating at the current time. Most of Avenue Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avenue Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avenue Therapeutics' price. Additionally, you may evaluate how the addition of Avenue Therapeutics to your portfolios can decrease your overall portfolio volatility.